Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study

Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized again within a year, and 10% experience another heart attack. Despite currently available medication, patients remain at risk of further episodes after a heart attack. Scientists have discovered that inflammation in the body plays a decisive role in the development and narrowing of arterial blockages (atherosclerosis). This study aims to investigate whether a new treatment that reduces inflammation can help improve the arteries of patients with CAD.
This study will examine whether blocking certain inflammation-related substances with a new medicinal product called ziltivekimab affects the buildup and composition of plaques (fatty deposits) in the coronary arteries. Special imaging diagnostic techniques will be used to look inside the arteries and check whether the treatment helps reduce the narrowing caused by dangerous plaques, which can lead to future heart attacks.
This is a clinical study in which participants are randomly divided into two groups (randomization): one group will receive the new treatment ziltivekimab and other group will receive a placebo (a harmless substance with no active ingredients). Both groups will continue to receive standard treatment for heart attacks. The study lasts approximately 15 months per participant.
The full scientific title of the trial is: Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A study with serial multi-vessel imaging obtained using intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography techniques.

开始日期2025-12-19

申办/合作机构

ECRI-1 BV

[+3]

NCT06118281

/ Recruiting临床3期

ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

开始日期2024-06-25

申办/合作机构

Novo Nordisk A/S

[+1]

NCT06263244

/ Active, not recruiting临床3期IIT

Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping

The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.

开始日期2024-05-03

申办/合作机构-

100 项与齐替韦单抗相关的临床结果

登录后查看更多信息

100 项与齐替韦单抗相关的转化医学

登录后查看更多信息

100 项与齐替韦单抗相关的专利（医药）

登录后查看更多信息

项与齐替韦单抗相关的文献（医药）

2026-10-01·PHARMACOLOGY & THERAPEUTICS

Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring

Review

作者: Zhen, Xin ; Ouyang, Hua ; Tang, Hairong ; Li, Yafeng ; Yang, Xiaofeng ; Sun, Juan ; Chai, Yuanmin ; Zhi, Wenqiang ; Song, Wenzhu ; Xu, Keman ; Li, Ruilin ; Wang, Hong ; Fan, Qiuxia ; Huan, Chengyu

Cardiovascular-kidney-metabolic (CKM) syndrome, formally defined by the American Heart Association in 2023, affects approximately 90% of US adults, who meet criteria for stage 1 or higher. The rapid convergence of multiple drug classes on CKM pathways, SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, ARNI, and interleukin-directed therapies, has created an urgent need for pharmacologically grounded frameworks that guide drug selection, interpret biomarker responses, and monitor target engagement across interconnected organ systems. This review proposes a three-dimensional biomarker-guided approach to precision pharmacotherapy in CKM syndrome. In the organ-specific dimension, we map key biomarkers to their corresponding drug targets and elucidate the molecular mechanisms underlying drug-biomarker interactions: SGLT2 inhibitors attenuate myocardial injury through metabolic substrate shifting toward ketone body utilization and, based on preclinical evidence, NHE1 inhibition; neprilysin selectivity of sacubitril/valsartan explains the differential natriuretic peptide response; and tubuloglomerular feedback mediates the renoprotective hemodynamic effects of SGLT2 inhibitors. In the pathway-specific dimension, we identify cross-system biomarkers, such as hs-CRP, IL-6, galectin-3, GDF-15, and FGF21,which reveal shared druggable targets spanning the IL-1β/NLRP3 inflammasome axis (canakinumab, colchicine), IL-6 trans-signaling (ziltivekimab), and FGF21/β-klotho metabolic signaling. In the temporal dimension, we demonstrate how serial biomarker trajectories serve as pharmacodynamic readouts that distinguish therapeutic drug effects from disease progression, including the initial eGFR dip with SGLT2 inhibitors and natriuretic peptide changes during combination therapy. Central to this framework is the concept of "pharmacological phenotyping", using multi-biomarker panels to define drug-responsive pathophysiological states that directly inform therapeutic selection, analogous to companion diagnostics in oncology. We further present a comprehensive drug-biomarker interaction matrix with pharmacological rationale and analyze the emerging drug development pipeline, including RNA-based Lp(a) therapeutics, FGF21 analogues, galectin-3 inhibitors, and in vivo CAR-T anti-fibrotic approaches. This framework provides a practical roadmap for biomarker-guided precision pharmacotherapy in CKM syndrome.

2026-01-01·JAMA Cardiology

Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial

Article

作者: Tuttle, Katherine ; Baeres, Florian M. M. ; Perkovic, Vlado ; Lincoff, A. Michael ; Hveplund, Anders ; Hovingh, G. Kees ; Navar, Ann Marie ; Engelmann, Mads M. D. ; Marx, Nikolaus ; Sattar, Naveed ; Ridker, Paul M

Importance:

Cardiovascular inflammation is a major determinant of atherosclerotic disease, and inhibition of the central signaling cytokine, interleukin 6 (IL-6), is a promising target for intervention. Patients with chronic kidney disease (CKD) commonly have plasma elevations of inflammatory biomarkers, such as high-sensitivity C-reactive protein (hsCRP) and IL-6, and are at high risk for life-threatening atherosclerotic events as well as loss of kidney function and might therefore benefit from IL-6 inhibition.

Observations:

The Ziltivekimab Cardiovascular Outcomes Trial (ZEUS; NCT05021835 ) will determine the safety and efficacy of IL-6 inhibition with ziltivekimab among patients with atherosclerotic cardiovascular disease (ASCVD), CKD, and systemic inflammation. ZEUS is a multinational, double-blind, placebo-controlled, event-driven, randomized clinical trial inclusive of 6376 participants with ASCVD, CKD, and an hsCRP level greater than or equal to 2 mg/L who were randomized in a 1:1 fashion to receive either ziltivekimab, 15 mg, administered subcutaneously every month or matching placebo. At randomization, mean age was 69.5 years, 27.5% were female, 92.0% had hypertension, 65.7% had diabetes, and 41.3% had heart failure. At baseline, the mean estimated glomerular filtration rate (eGFR) was 44.5 mL/min/1.73 m 2 , mean low-density lipoprotein cholesterol level was 77.7 mg/dL, median hsCRP level was 4.5 mg/L, and median IL-6 level was 4.9 pg/mL. At enrollment, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were being used by 36.8% and 11.3% of the cohort, respectively. The primary outcome is 3-point major adverse cardiovascular events. Secondary cardiovascular outcomes include (1) an expanded major adverse cardiovascular event outcome including hospitalization for unstable angina requiring urgent coronary revascularization, (2) hospitalizations for heart failure or urgent heart failure visits or cardiovascular death, and (3) all-cause mortality. The secondary kidney outcome is a composite of greater than 40% decline in eGFR, eGFR less than 15 mL/min/1.73 m 2 , dialysis, kidney transplant, death from kidney disease, or cardiovascular death.

Conclusions and Relevance:

The ZEUS randomized clinical trial will formally test the hypothesis that IL-6 inhibition with ziltivekimab will lower incident cardiovascular event rates and potentially slow kidney decline among participants with known ASCVD, CKD, and elevated hsCRP. If successful, the ZEUS trial would provide a fully novel approach for prevention of myocardial infarction, stroke, cardiovascular death, and kidney function decline among high-risk patients with CKD.

2026-01-01·Frontiers in Immunology

Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy.

Review

作者: Wu, Yutao ; Zhou, Chang ; Gong, Xinwang

Despite major advances in lipid-lowering therapy and stent technology, a substantial proportion of patients undergoing contemporary percutaneous coronary intervention (PCI) experience recurrent major adverse cardiovascular events (MACE) driven by persistent residual inflammatory risk (RIR). This Perspective highlights that, once LDL-C is optimized below 70 mg/dL, RIR-quantified by high-sensitivity C-reactive protein (hsCRP ≥2 mg/L)-emerges as the dominant modifiable driver of recurrent events. Landmark meta-analyses and large registries demonstrate that persistent elevation of hsCRP at 1 month post-PCI occurs in approximately 43% of patients and independently predicts 12-month MACE (RR 1.64), all-cause mortality (RR 3.25), and other adverse outcomes, outperforming residual cholesterol risk after multivariable adjustment. Mechanistically, the acute-phase hsCRP surge induced by procedural injury resolves by 4-6 weeks, after which the 1-month value reliably reflects ongoing NLRP3 inflammasome activation, IL-1β/IL-6 signaling, and macrophage-driven plaque inflammation rather than transient artefacts. Accordingly, we propose a new "dual-target" definition of optimal secondary prevention: achievement of both LDL-C <70 mg/dL and hsCRP <2 mg/L at the 1-month landmark. This biomarker-guided approach represents a hypothesis-generating framework to enable precision deployment of low-dose colchicine or IL-6 pathway inhibitors (e.g., ziltivekimab) in patients with persistent RIR, directly addressing the enrichment gap observed in neutral broad anti-inflammatory trials such as CLEAR-SYNERGY. We therefore propose consideration of routine 1-month hsCRP reassessment as a potential future Class IIa recommendation in ESC/ACC guidelines. This strategy may transform silent residual inflammatory risk into a precisely treatable immunologic target, pending prospective validation in dedicated trials.

148

项与齐替韦单抗相关的新闻（医药）

16 小时之前

·丁香园 Insight 数据库

超 21 亿美元引进，诺和诺德终止 IL-6 单抗两项 III 期临床

9 月 7 日，据外媒报道，诺和诺德提前终止了 IL-6 单抗 ziltivekimab（泽韦奇单抗）的另外两项后期研究，原因是研究数据监测委员会认定这两项研究成功的可能性很小。来源：EndpointsNews 一位发言人表示，针对心力衰竭的 HERMES 和 ATHENA 两项临床试验在委员会审查了所有数据后，已提前终止。来源：丁香园 Insight 数据库值得一提的是，今年 7 月， ziltivekimab 的 III 期 ZEUS 研究失败，没有达到心血管死亡、非致死性心肌梗死和非致死性卒中的 3 点 MACE 主要终点。ZEUS 旨在评估 ziltivekimab 是否可以降低心血管疾病、慢性肾脏疾病和炎症患者发生心血管事件的风险，实际入组 6385 名受试者。不过，ziltivekimab 另一项 III 期 ARTEMIS 研究仍在进行中，预计 2027 上半年公布数据。ARTEMIS 旨在评估 Ziltivekimab 对急性心肌梗死患者心血管结局的影响。 Ziltivekimab 是一款全人源单克隆抗体，通过抑制 IL-6 来减少全身炎症，其经过长效化改造以延长半衰期，仅需每月一次皮下注射给药。2020 年 6 月，诺和诺德以 7.25 亿美元首付款、潜在总额超 21 亿美元收购阿斯利康子公司 Corvidia Therapeutics 囊获了该产品。编辑：月牙封面来源：企业logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，不构成任何投资建议，也不作治疗方案推荐和介绍。如有就医需求，请咨询和联系正规医疗机构

临床3期并购临床成功临床结果

2026-09-08

·微信

超 21 亿美元引进，诺和诺德终止 IL-6 单抗两项 III 期临床

关注并星标CPHI制药在线 9 月 7 日，据外媒报道，诺和诺德提前终止了 IL-6 单抗 ziltivekimab（泽韦奇单抗）的另外两项后期研究，原因是研究数据监测委员会认定这两项研究成功的可能性很小。来源：EndpointsNews 一位发言人表示，针对心力衰竭的 HERMES 和 ATHENA 两项临床试验在委员会审查了所有数据后，已提前终止。来源：丁香园 Insight 数据库值得一提的是，今年 7 月， ziltivekimab 的 III 期 ZEUS 研究失败，没有达到心血管死亡、非致死性心肌梗死和非致死性卒中的 3 点 MACE 主要终点。ZEUS 旨在评估 ziltivekimab 是否可以降低心血管疾病、慢性肾脏疾病和炎症患者发生心血管事件的风险，实际入组 6385 名受试者。不过，ziltivekimab 另一项 III 期 ARTEMIS 研究仍在进行中，预计 2027 上半年公布数据。ARTEMIS 旨在评估 Ziltivekimab 对急性心肌梗死患者心血管结局的影响。 Ziltivekimab 是一款全人源单克隆抗体，通过抑制 IL-6 来减少全身炎症，其经过长效化改造以延长半衰期，仅需每月一次皮下注射给药。2020 年 6 月，诺和诺德以 7.25 亿美元首付款、潜在总额超 21 亿美元收购阿斯利康子公司 Corvidia Therapeutics 囊获了该产品。 END 扫码领取2026年CPHI深圳展门票来源：丁香园Insight数据库声明：本网站内容仅出于传递更多信息之目的。并不代表制药在线立场。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

2026-09-08

·新浪看点

新浪美股热点小时报丨2026年09月08日18时_今日实时美股热点速递

1、韩国散户，撤退！（来源：经济参考报）9月以来，全球科技股回暖带动韩国半导体相关ETF表现抢眼，但股价回升之际，个人投资者却选择获利了结，相关产品遭遇大规模净卖出。展望后市，机构对于科技板块后市整体持偏积极态度，认为算力基建热潮对存储需求的拉动或超预期；不过也有机构提醒，美债利率高企等外部因素仍是市场不可忽视的风险点。韩国个人投资者获利了结在经历了7—8月份的大幅回调后，多只韩国本土半导体杠杆ETF在9月迎来集体反弹。韩国交易所及科斯康CHECK（韩国专业金融信息终端）发布的数据显示，9月1日至9月7日期间，韩国国内上市ETF收益率排名前十的产品中，多达9只为半导体相关品种。http://k.sina.com.cn/article_5953190046_162d6789e06703rg84.html2、《2026中概股赴美上市明显降温：迄今仅3家，纳斯达克门槛再提高》（来源：中善讲资本）进入2026年9月，中概股赴美上市正在出现一个非常明显的变化：企业还在排队，但真正完成上市的已经越来越少。按照SEC相关地域口径，并统计IPO、RTO/De-SPAC、转板及双重上市等登陆纳斯达克、纽交所体系主要交易市场的方式，截至目前，2026年仅有3家中概企业完成赴美上市。其中，中国大陆企业为大搜车（NASDAQ）和龙电华鑫（NYSE）；香港地区则有1家企业完成NYSE American上市。相比过去几年中小型中概企业集中登陆美股的情况，今年的赴美上市数量已经降至近年来罕见低位。更值得注意的是，不只是IPO数量下降。http://k.sina.com.cn/article_5952915705_162d248f906703nnm2.html3、热门中概股，盘前集体下跌9月8日美股盘前，三大股指期货齐跌，截至发稿，道指期货跌0.3%，纳斯达克100指数期货跌0.31%，标普500指数期货跌0.25%。热门中概股盘前普遍下跌，百度大跌逾7%，蔚来、京东、阿里巴巴跌逾1%，拼多多、小鹏集团均下挫。半导体、存储芯片股盘前多数上涨，英特尔涨超2%，SK海力士、超威半导体涨超1%，闪迪、美光科技、西部数据、希捷科技等均走高。大型科技股盘前涨跌不一，Meta跌超1%，微软、苹果、谷歌、特斯拉小幅下跌；SpaceX、英伟达微涨。港股方面，恒指报收25317.18点，跌0.38%，恒生科技指数报收4454.85点，跌1.61%。http://finance.sina.com.cn/wm/2026-09-08/doc-inirceww9443387.shtml4、全球市场持续对各类冲击免疫汇丰银行列出可能终结这一态势的风险因素核心要点汇丰银行表示，在企业盈利向好、财富增值以及央行大规模兜底政策的支撑下，市场多次对各类冲击置之不理。该行称，若市场感知到央行不再提供托底支持，或将重创市场，但出现这种情景的可能性较低。　　近些年来全球市场接连遭遇重重冲击，却都安然度过。不过汇丰银行认为，有若干事态演变，最终有可能终结市场这份韧性。　　该行在周一发布的研报中指出，主要风险包括企业税上调、私营部门债务再度攀升、股债联动关系发生转变；另外，市场预期的央行托底支持一旦消退，也将考验市场抗风险能力。http://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4624511.shtml5、美股观察｜美股市场并非只在交易“增长韧性”（来源：博时基金）一、美国宏观经济数据8月ISM制造业PMI为54.6，低于市场预期55.2，也低于7月的55.6，但仍连续第8个月位于扩张区间。从分项看，新订单指数降至53.7，生产指数58.3，就业指数51.2，供应商交付59.3。这组数据说明制造业景气并没有被破坏，只是从高位略有放缓。8月ISM服务业PMI升至55.4，显著高于市场预期的54.1/54.2，也高于7月的54.1。8月新增非农16.2万人，远高于市场预期的5.5万-6.5万人；失业率4.1%，符合预期；6月和7月合计上修5.5万人；劳动参与率回升至61.6%；平均时薪同比降至3.1%，环比升至0.3%。http://finance.sina.com.cn/money/fund/jjzl/2026-09-08/doc-inirceww4627563.shtml6、美股大型科技股盘前涨跌互现，SK海力士涨超1%每经AI快讯，9月8日，美股大型科技股盘前涨跌互现，SK海力士涨超1%，美光科技涨0.8%，SpaceX涨0.4%，英伟达涨0.3%；特斯拉持平；Meta跌0.9%，微软跌0.6%，亚马逊跌0.5%，谷歌A跌0.3%，苹果跌0.2%。http://finance.sina.com.cn/roll/2026-09-08/doc-inirceww4587629.shtml7、高盛重申对雀巢的买入评级欧洲必需消费品板块整体行情向好，受高盛重申对雀巢的买入评级、认为其具备强劲投资逻辑推动，雀巢股价最高上涨2.6%。截至中欧时间上午9点35分，该股上涨2.3%，年内表现由负转正。瑞银编制的欧洲必需消费品一篮子股票指数上涨约1%。高盛分析师奥利维耶·尼科莱表示，雀巢的业务转型进展符合预期，主要受益于景气度较高的宠物护理业务增长提速，咖啡业务有所回暖；这两大板块合计占到集团近一半营收。http://k.sina.com.cn/article_5953740931_162dee08306703xzwg.html8、EVERPURE盘前上涨2.5%，此前该公司将加入标普500指数，9月21日起生效。EVERPURE盘前上涨2.5%，此前该公司将加入标普500指数，9月21日起生效。http://k.sina.com.cn/article_5953189932_162d6782c06704xj06.html9、美股异动丨诺华制药盘前重挫约13% DM1药物III期临床试验未达到主要终点诺华制药(NVS.US)盘前重挫12.94%，报139.29美元。消息面上，诺华制药宣布，其评估del-desiran治疗1型强直性肌营养不良(DM1)的III期HARBOR研究未达到主要终点。数据显示，与安慰剂相比，患者视频手部张开时间(vHOT)未出现具有统计学意义的改善。诺华表示，研究在次要终点和探索性分析中观察到临床活性迹象，安全性总体与此前数据一致。公司将进一步分析完整数据，并与监管机构沟通后确定后续开发路径。http://finance.sina.com.cn/stock/bxjj/2026-09-08/doc-inirceww4589473.shtml10、【狙击电波】半导体设备板块活跃，如何避开涨了追跌了割的陷阱http://finance.sina.com.cn/stock/s/2026-09-08/doc-inirceww4601304.shtml11、美股异动｜安进盘前跌5.4%，诺华同靶点药物III期临床失败，Lp(a)赛道遭重创安进(AMGN.US)盘前跌5.4%。消息面上，诺华于9月4日公布，其与Ionis联合开发的降脂药物Pelacarsen，在名为Lp(a)HORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp(a)靶点进行心血管结局验证的III期药物。它的失败，对整个Lp(a)药物研发赛道都是个打击，因为这意味着“降低Lp(a)水平就能明确降低心血管风险”这个核心假设遭到了挑战。因此，市场担忧情绪蔓延到了同样在开发Lp(a)药物的安进身上。多家分析机构认为，诺华的失败削弱了但并未完全推翻Lp(a)这一靶点的可行性。http://finance.sina.com.cn/stock/bxjj/2026-09-08/doc-inirceww4606846.shtml12、美股异动丨诺和诺德盘前跌逾1% 终止两项心血管临床试验诺和诺德(NVO.US)盘前跌1.14%，报46.07美元。消息面上，诺和诺德终止了其心血管试验性药物的两项额外临床试验。今年早些时候，诺和诺德曾表示，Ziltivekimab未能降低心肌梗死和中风的风险，这削弱了市场对其其他正在进行的临床研究的预期。这家丹麦制药商周一表示，已叫停评估Ziltivekimab是否有助于心力衰竭患者的两项试验，这两项试验分别针对不同的治疗结局。http://finance.sina.com.cn/stock/bxjj/2026-09-08/doc-inirceww9429372.shtml13、科伦坡全股指数收盘下跌 0.3%，报 21568.40 点。科伦坡全股指数收盘下跌 0.3%，报 21568.40 点。http://k.sina.com.cn/article_5953740931_162dee08306703y07o.html14、阿斯麦美股盘前涨超2%阿斯麦美股盘前涨超2%，现报1749.75美元。http://k.sina.com.cn/article_5953190046_162d6789e06703rgfk.html

100 项与齐替韦单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12807	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	临床3期	奥地利	Novo Nordisk A/S	2025-12-18
冠心病	临床3期	丹麦	Novo Nordisk A/S	2025-12-18
冠心病	临床3期	意大利	Novo Nordisk A/S	2025-12-18
冠心病	临床3期	荷兰	Novo Nordisk A/S	2025-12-18
冠心病	临床3期	西班牙	Novo Nordisk A/S	2025-12-18
冠心病	临床3期	瑞士	Novo Nordisk A/S	2025-12-18
急性心肌梗塞	临床3期	美国	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	中国	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	日本	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	阿根廷	Novo Nordisk A/S	2024-06-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04626505 (RESCUE-2, CTgov)	临床2期	炎症 \| 慢性肾病	36	Ziltivekimab (Ziltivekimab 15 mg)	築艱鑰襯鬱齋糧製廠觸(遞艱鬱觸鹹衊積淵膚鏇) = 鹹憲齋壓襯鏇鏇選窪構製夢襯夢襯衊衊遞襯繭 (窪鹽願憲蓋窪齋積遞鑰, 襯鑰齋鏇鹹醖遞鏇淵鹹 ~ 蓋糧醖夢夢願窪襯網壓) 更多	-	2026-05-06
				Ziltivekimab (Ziltivekimab 30 mg)	築艱鑰襯鬱齋糧製廠觸(遞艱鬱觸鹹衊積淵膚鏇) = 淵鏇蓋鏇遞齋製願鬱積製夢襯夢襯衊衊遞襯繭 (窪鹽願憲蓋窪齋積遞鑰, 糧獵積簾簾遞積獵蓋廠 ~ 願鹽餘夢餘糧窪壓製構) 更多
NCT03926117 (RESCUE, Pubmed) 人工标引	临床2期	炎症 \| 慢性肾病 C-reactive Protein Expression	261	Ziltivekimab 7.5 mg	願廠壓繭觸襯壓鏇醖構(構範積鹽膚襯餘衊鹹願) = 淵製鹽觸糧繭窪選鹹襯齋廠壓積範鹽鏇願艱網 (壓壓鹹淵淵繭淵衊憲醖 )	积极	2024-01-01
				Ziltivekimab 15 mg	願廠壓繭觸襯壓鏇醖構(構範積鹽膚襯餘衊鹹願) = 衊獵糧淵鏇積網鬱鬱艱齋廠壓積範鹽鏇願艱網 (壓壓鹹淵淵繭淵衊憲醖 )
NCT04626505 (RESCUE-2, Pubmed \| J Cardiol)	临床2期	动脉粥样硬化 high-sensitivity C-reactive protein (hsCRP)	-	Ziltivekimab 15mg	製鹹齋選衊願鏇範範鬱(艱衊醖鑰鑰廠淵衊鏇齋) = 製網鏇範獵顧鑰觸夢襯衊築艱衊蓋願鑰窪鹹鬱 (願鹽鏇鬱艱鏇築顧襯顧 )	积极	2023-10-01
				Ziltivekimab 30mg	製鹹齋選衊願鏇範範鬱(艱衊醖鑰鑰廠淵衊鏇齋) = 齋願醖窪遞憲觸獵遞選衊築艱衊蓋願鑰窪鹹鬱 (願鹽鏇鬱艱鏇築顧襯顧 )
NCT03926117 (RESCUE \| RESCUE Trial, CTgov)	临床2期	炎症 \| 慢性肾病	264	Ziltivekimab (Placebo)	鏇鹽鏇鏇淵衊構鹽餘願(艱範廠壓膚鹽廠淵壓獵) = 顧襯網衊壓範遞餘簾構憲構醖簾選鏇範夢範選 (夢積壓鏇繭繭淵淵鬱願, 糧壓獵糧製積鹽鑰醖築 ~ 網淵淵網膚憲淵襯簾壓) 更多	-	2023-08-09
				Ziltivekimab (Ziltivekimab 7.5 mg)	鏇鹽鏇鏇淵衊構鹽餘願(艱範廠壓膚鹽廠淵壓獵) = 鏇艱餘憲選鏇選餘範鬱憲構醖簾選鏇範夢範選 (夢積壓鏇繭繭淵淵鬱願, 壓構襯憲齋衊醖衊壓構 ~ 廠鬱築淵鹹網構餘鏇鹹) 更多
NCT03926117 (RESCUE Trial, ASN2021)	临床2期	慢性肾病 serum hemoglobin \| iron homeostasis \| high-sensitivity C-reactive protein	-	Ziltivekimab 7.5 mg	餘廠衊鏇鏇醖網築壓願(淵願醖繭鹹獵蓋壓壓觸) = 夢觸齋夢積選窪構選繭齋憲鹹糧製簾觸鬱膚遞 (憲醖醖繭壓範鑰觸蓋鹽 )	积极	2021-10-27
				Ziltivekimab 15 mg	餘廠衊鏇鏇醖網築壓願(淵願醖繭鹹獵蓋壓壓觸) = 齋繭簾範淵醖製鏇築鏇齋憲鹹糧製簾觸鬱膚遞 (憲醖醖繭壓範鑰觸蓋鹽 )
NCT02868229 (CTgov)	临床1/2期	贫血	61	Placebo (Placebo)	網壓築構鏇壓壓簾蓋觸 = 簾襯觸衊壓夢淵鹽糧遞壓壓鏇糧構膚簾壓積衊 (鏇顧夢網觸構艱鹹夢簾, 顧範齋窪鹽糧鹽積鹽製 ~ 構繭網願憲範製築選襯) 更多	-	2021-07-30
				COR-001 (COR-001)	選構選積窪範醖範鹹淵(築築簾願餘襯窪齋繭壓) = 醖廠構鑰醖觸顧壓鬱製艱襯遞齋積簾鏇獵廠築 (齋選築廠鏇襯艱鑰淵壓, 鏇築觸選繭醖壓積襯憲 ~ 製鏇願廠夢餘壓齋衊鏇)
NCT03926117 (RESCUE, Pubmed \| Lancet)	临床2期	动脉粥样硬化	264	Placebo	鏇齋鹹壓鹹鏇淵製繭淵(夢壓衊鑰夢積齋衊窪衊) = 鑰鹽遞淵選顧衊鹹襯鑰願鑰窪窪顧簾憲觸廠範 (淵選鬱糧鑰廠壓鑰醖壓 )	积极	2021-05-14
ASN2019	临床1期	慢性肾病	12	COR-001 5 mg	蓋餘繭齋夢窪壓選築膚(選糧鹽鬱簾選鏇膚製蓋) = 餘獵鏇壓憲積顧齋觸觸窪膚淵糧製憲構窪壓淵 (鬱餘蓋範艱鬱鹽範膚願 )	积极	2019-11-05
				COR-001 15 mg	蓋餘繭齋夢窪壓選築膚(選糧鹽鬱簾選鏇膚製蓋) = 淵襯簾觸衊衊遞範鹹壓窪膚淵糧製憲構窪壓淵 (鬱餘蓋範艱鬱鹽範膚願 )